---
title: "Xenetic Biosciences | 8-K: FY2026 Q1 Revenue: USD 800 K"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286257619.md"
datetime: "2026-05-13T12:07:12.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286257619.md)
  - [en](https://longbridge.com/en/news/286257619.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286257619.md)
---

# Xenetic Biosciences | 8-K: FY2026 Q1 Revenue: USD 800 K

Revenue: As of FY2026 Q1, the actual value is USD 800 K.

EBIT: As of FY2026 Q1, the actual value is USD -500 K.

#### Royalty Revenue

Royalty revenue for the three months ended March 31, 2026, increased approximately 36% to approximately $0.8 million, compared to approximately $0.6 million for the comparable prior year period. This increase was primarily driven by increased royalty payments recognized under Xenetic Biosciences, Inc.’s sublicense agreement with Takeda Pharmaceuticals Co. Ltd.

#### Research and Development Expenses

Research and development expenses for the three months ended March 31, 2026, decreased approximately 25% to approximately $0.7 million, from approximately $0.9 million for the comparable prior year period. This decrease was primarily due to lower preclinical and exploratory study costs, partially offset by increased manufacturing development efforts supporting the company’s DNase I program.

#### General and Administrative Expenses

General and administrative expenses for the three months ended March 31, 2026, decreased by approximately 1.4% to approximately $0.6 million, from approximately $0.7 million in the comparable quarter in 2025. The decrease was primarily due to lower personnel and share-based expenses related to the interim Chief Executive Officer, substantially offset by an increase in legal expenses related to the strategic review process.

#### Net Loss

Net loss for the quarter ended March 31, 2026, decreased approximately 49% to approximately $0.5 million, compared to approximately $0.9 million for the same period in 2025.

#### Cash and Cash Equivalents

Xenetic Biosciences, Inc. ended the first quarter of 2026 with approximately $7.3 million in cash and cash equivalents, compared to approximately $7.9 million as of December 31, 2025.

#### Outlook / Guidance

Xenetic Biosciences, Inc. is continuing to evaluate strategic alternatives to maximize shareholder value. The company remains focused on advancing the translational, manufacturing, and clinical foundation of its proprietary DNase I platform. This includes progressing its systemic DNase program into clinical trials as an adjunctive therapy for pancreatic carcinoma and locally advanced or metastatic solid tumors.

### Related Stocks

- [XBIO.US](https://longbridge.com/en/quote/XBIO.US.md)

## Related News & Research

- [Xenetic Biosciences Reports First Quarter 2026 Financial Results and Highlights Continued Advancement of DNase Oncology Platform | XBIO Stock News](https://longbridge.com/en/news/286257227.md)
- [Xenetic Biosciences' Q1 royalty revenue rises, net loss narrows](https://longbridge.com/en/news/286258667.md)